{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:48:51Z","timestamp":1773294531818,"version":"3.50.1"},"reference-count":167,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T00:00:00Z","timestamp":1228176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The following comprehensive review describes the evolution of stimulant drug formulations used in the treatment of attention\u2010deficit\/hyperactivity disorder (ADHD). Emphasis is placed on the basic and clinical pharmacology of the dl\u2010methylphenidate (MPH) transdermal system (MTS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The pharmacokinetic and pharmacodynamic literature pertaining to MPH and amphetamine enantiomers was reviewed in the context of ADHD therapy and MTS as a treatment option.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MTS incorporates MPH into an adhesive monolithic matrix, using the free base form of the drug to facilitate transdermal absorption. MTS technology minimizes contact dermatitis by eliminating to need for percutaneous penetration enhancers. After a lag time of approximately 2\u2009h, plasma concentrations of the therapeutic d\u2010MPH isomer become detectable, then continuously rise over the course of the recommended 9\u2009h wear time. Concentrations of l\u2010MPH typically attain 40\u201350% that of d\u2010MPH (vs. 1\u20132% following oral MPH). Unauthorized MTS removal poses some misuse liability and over 50% of MTS drug content remains in the discarded system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While liquid or chewable MPH formulations overcome potential swallowing difficulties, as do sprinkled once\u2010daily extended\u2010release (ER) MPH products, only MTS addresses swallowing difficulties while also offering a flexible individualized MPH exposure time in a once\u2010daily MPH regimen. Copyright \u00a9 2008 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.992","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T15:14:35Z","timestamp":1228230875000},"page":"1-17","source":"Crossref","is-referenced-by-count":27,"title":["Evolution of stimulants to treat ADHD: transdermal methylphenidate"],"prefix":"10.1002","volume":"24","author":[{"given":"Kennerly S.","family":"Patrick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur B.","family":"Straughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeb S.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,12,2]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"654","volume-title":"Remington: The Science and Practice of Pharmacy","author":"Abdou HM","year":"2000"},{"key":"e_1_2_1_3_1","volume-title":"The Impact of Stereochemisrty on Drug Development and Use","author":"Aboul\u2010Enein HY","year":"1997"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00827-8"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666080-00007"},{"key":"e_1_2_1_6_1","unstructured":"AndreasonPJ.2005. Methylphenidate transdermal patch.www.fda.gov\/ohrms\/dockets\/ac\/05\/slides\/2005\u20104195 S1 01 FDA\u2010Andreason.ppt"},{"issue":"1237","key":"e_1_2_1_7_1","first-page":"49","article-title":"Transdermal methylphenidate (Daytrana) for ADHD","volume":"48","author":"Anonymous","year":"2006","journal-title":"Med Lett"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.27"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/002221947801100303"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.542"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1972.01750300078015"},{"key":"e_1_2_1_12_1","unstructured":"BaldessariniB CambellA.2001. Method of dopamine inhibition using l\u2010methylphenidate. US Patent 6 221 883."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000805"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200212000-00020"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225140-00004"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(03)00143-7"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198909000-00020"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709020-00007"},{"key":"e_1_2_1_19_1","first-page":"836","volume-title":"Remington: The Practice and Science of Pharmacy","author":"Block LH","year":"2000"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301445"},{"key":"e_1_2_1_21_1","first-page":"390","article-title":"Fentanyl transdermal system overdose secondary to cutaneous hyperthemlia","volume":"77","author":"Boswell MV","year":"1992","journal-title":"Anesth Analg"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.94.3.577"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1542\/peds.5.1.24","article-title":"Benzedrine and Dexedrine in the treatment of children's behavior disorders","volume":"5","author":"Bradley C","year":"1950","journal-title":"Pediatrics"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)60699-3"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.05.007"},{"key":"e_1_2_1_26_1","first-page":"140","article-title":"In vivo determination of zero\u2010order absorption from a transdermal glycerol trinitrate system","volume":"39","author":"Cefali EA","year":"1993","journal-title":"Eur J Pharm Biopharm"},{"key":"e_1_2_1_27_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1542\/peds.72.1.56","article-title":"Methylphenidate hydrochloride given with or before breakfast: II. Effect on plasma concentrations of methylphenidate and ritalinic acid","volume":"72","author":"Chan YP","year":"1983","journal-title":"Pediatrics"},{"key":"e_1_2_1_28_1","unstructured":"Concerta.2006. Janssen\u2010Ortho. Product monograph 25 July; No: 106348."},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.703"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.883"},{"key":"e_1_2_1_31_1","unstructured":"DavidsonEJ CraigF.2000. Treatment of convulsive states. US Patent 7384959."},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-001-0962-5"},{"key":"e_1_2_1_33_1","unstructured":"DAWN: Drug Abuse Warning Network.2003. Annual emergency department data. DHHS. Substance Abuse and Mental Health Services Administration."},{"key":"e_1_2_1_34_1","first-page":"255","article-title":"Is the l\u2010threo enantiomer of methylphenidate (Ritalin) inactive in the brain when given orally? [abstr]","volume":"8","author":"Ding YS","year":"2002","journal-title":"Am Col Neuropsychopharmacol"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20046"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1990.1.7"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/10598405070230060801"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(91)90100-G"},{"key":"e_1_2_1_39_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-3565(25)30016-9","article-title":"Metabolism and disposition of methylphenidate\u201014C in man and animals","volume":"191","author":"Faraj BA","year":"1974","journal-title":"J Exper Pharmacol Ther"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31806ad1d7"},{"key":"e_1_2_1_41_1","first-page":"123","article-title":"The effects of transdermal methylphenidate with reference to Concerta in ADHD","volume":"32","author":"Findling R","year":"2005","journal-title":"Sci Proc Am Acad Child Adolesc Psychiatry"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0120"},{"key":"e_1_2_1_43_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0608614"},{"key":"e_1_2_1_44_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016262815984"},{"key":"e_1_2_1_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200109000-00023"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-2012-6"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-7743(02)37003-9"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP40175"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)60486-6"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1385\/1592598919"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(18)30255-7"},{"key":"e_1_2_1_52_1","first-page":"547","volume-title":"Goodman and Gilman's the Pharmacological Basis of Therpeutics","author":"Gutstein HB","year":"2006"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46466"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620090-00002"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(02)00053-4"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199402000-00001"},{"key":"e_1_2_1_57_1","first-page":"69","article-title":"Heat\u2010enhanced drug delivery: a survey paper","volume":"2","author":"Hull W","year":"2002","journal-title":"J Appl Res Clin Exp Ther"},{"key":"e_1_2_1_58_1","unstructured":"HurwitzJ.2001.Swallowing tablets and capsules: a guide for parents care givers and children 4 years and up. Duke Pediatric Clinical Research Program Room 1080 Duke South Hospital Durham NC 27710."},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199109000-00012"},{"key":"e_1_2_1_60_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0213"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770030024003"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(97)00138-8"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.5.6.681"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.08.065"},{"key":"e_1_2_1_65_1","first-page":"199","volume-title":"The Pathology of Drug Abuse","author":"Karch SB","year":"1996"},{"key":"e_1_2_1_66_1","unstructured":"KhetaniV FaleckH.2004. Method of diminishing co\u2010abuse potential. US Patent App. 20050239830."},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-200204000-00013"},{"key":"e_1_2_1_68_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.6.4.367"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.8.1062674"},{"key":"e_1_2_1_70_1","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3565(24)38829-9","article-title":"Locomotor effects of acute and repeated threshold doses of amphephetamine and methylphenidate: Relative roles of dopamine and norepinephrine","volume":"296","author":"Kuczenski R","year":"2001","journal-title":"J Pharmacol Exper Ther"},{"key":"e_1_2_1_71_1","volume-title":"Cocaine Pharmacology, Physiology and Clinical Strategies","author":"Lakoski JM","year":"1992"},{"key":"e_1_2_1_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.358"},{"key":"e_1_2_1_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.11.030"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/10.5.209"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2003.16.5.711"},{"key":"e_1_2_1_76_1","first-page":"526","article-title":"Methylphenidate: increased abuse or appropriate use?","volume":"39","author":"Llana ME","year":"1999","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_1_77_1","unstructured":"MantelleJ DixonTA.2001. Compositions and methods for treatment of attention deficit disorder and attention deficit\/hyperactivity disorder with methylphenidate. US Patent 6 210 705 B1."},{"key":"e_1_2_1_78_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.687"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181733560"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.12.1281.32697"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342040-00007"},{"key":"e_1_2_1_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000183461.18907.bc"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ipharm.2008.05.012"},{"key":"e_1_2_1_84_1","unstructured":"McDermottC.2006.FDA warns consumers not to use Triaminic vapor patch.FDA News 19 June P06\u2013P82."},{"key":"e_1_2_1_85_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.7.3.208"},{"key":"e_1_2_1_86_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054705284089"},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(81)90022-6"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007560500301"},{"key":"e_1_2_1_89_1","unstructured":"MidhaKK TeicherM KumarV.2002. Method of treating depression using l\u2010threo\u2010methylphenidate. US Patent 6 395 752."},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022009080"},{"key":"e_1_2_1_91_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.4.762"},{"key":"e_1_2_1_92_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569528909062955"},{"key":"e_1_2_1_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-597X-2-1"},{"key":"e_1_2_1_94_1","unstructured":"Noven\/Shire.2005a.Pharmacokinetics\/pharmacodynamics summary NDA 21\u2010 514. 24 October: 1\u201343.http:\/\/fda.gov\/ohrms\/dockets\/ac\/o5\/briefing\/2005\u20104195 B1 01 02\u2010Noven\u2010Appendix\u20101.pdf[accessed 3 May 2007]."},{"key":"e_1_2_1_95_1","unstructured":"Noven\/Shire.2005b.Methylphenidate transdermal system NDA 21\u2010514. FDA Psychopharmacologic Drugs Advisory Committee Briefing Document. 2 December:1\u201330."},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7687.2005.00399.x"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068113"},{"key":"e_1_2_1_98_1","first-page":"109","volume-title":"Percutaneous Penetration Enhancers","author":"Pappinen S","year":"2006"},{"key":"e_1_2_1_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007308615"},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e3181515205"},{"key":"e_1_2_1_101_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666050-00007"},{"key":"e_1_2_1_102_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0022-5347(25)00340-4","article-title":"Pharmacology of the enantiomers of threo\u2010methylphenidate","volume":"241","author":"Patrick KS","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00142a021"},{"key":"e_1_2_1_104_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2.1.121"},{"key":"e_1_2_1_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1077(199711\/12)12:6<527::AID-HUP932>3.0.CO;2-U"},{"key":"e_1_2_1_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510100206"},{"key":"e_1_2_1_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100082"},{"key":"e_1_2_1_108_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0490989"},{"key":"e_1_2_1_109_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.13.2.111"},{"key":"e_1_2_1_110_1","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1542\/peds.86.2.226","article-title":"Relative efficacy of long\u2010acting stimulants on children with attention deficit\u2010hyperactivity disorder: a comparison of standard methylphenidate, sustained\u2010release methylphenidate, sustained\u2010release dextroamphetamine, and pemoline","volume":"86","author":"Pelham WE","year":"1990","journal-title":"Pediatrics"},{"key":"e_1_2_1_111_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000157548.48960.95"},{"key":"e_1_2_1_112_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1542\/peds.80.4.491","article-title":"Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder","volume":"80","author":"Pelham WE","year":"1987","journal-title":"Pediatrics"},{"key":"e_1_2_1_113_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10484-005-2172-0"},{"key":"e_1_2_1_114_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200204000-00017"},{"key":"e_1_2_1_115_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1542\/peds.98.2.301","article-title":"Medication for children with attentional disorders","volume":"98","author":"Perrin J","year":"1996","journal-title":"Pediatrics"},{"key":"e_1_2_1_116_1","first-page":"B43","article-title":"Pharmacokinetics of methylphenidate transdermal system in children with ADHD","volume":"131","author":"Pierce DM","year":"2005","journal-title":"52nd Sci Proc Am Acad Child Adolesc Psychiatry"},{"key":"e_1_2_1_117_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0148"},{"key":"e_1_2_1_118_1","doi-asserted-by":"publisher","DOI":"10.1383\/anes.2005.6.8.286"},{"key":"e_1_2_1_119_1","first-page":"217","article-title":"The story of four salts","volume":"4","author":"Popper CW","year":"1994","journal-title":"J Child Adolesc Psychiatry"},{"key":"e_1_2_1_120_1","doi-asserted-by":"publisher","DOI":"10.1002\/1615-4169(200107)343:5<379::AID-ADSC379>3.0.CO;2-4"},{"key":"e_1_2_1_121_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007299759"},{"key":"e_1_2_1_122_1","first-page":"369","volume-title":"Ritalin: Theory and Practice","author":"Quinn DMP","year":"2000"},{"key":"e_1_2_1_123_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000140455.96946.2b"},{"key":"e_1_2_1_124_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp032387"},{"key":"e_1_2_1_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.01.002"},{"key":"e_1_2_1_126_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666050-00006"},{"key":"e_1_2_1_127_1","unstructured":"RometschR.1958. Process for conversion of streoisomers US Patent 2 838 519."},{"key":"e_1_2_1_128_1","first-page":"56","article-title":"Chirality at work","author":"Rouhi AM","year":"2003","journal-title":"Chem Eng News"},{"key":"e_1_2_1_129_1","doi-asserted-by":"publisher","DOI":"10.1080\/15563650701665175"},{"key":"e_1_2_1_130_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2007.0039"},{"key":"e_1_2_1_131_1","first-page":"450","article-title":"The global market for ADHD medications","volume":"26","author":"Scheffler RM","year":"2007","journal-title":"Health Trends"},{"key":"e_1_2_1_132_1","first-page":"1057","article-title":"Stereochemical studies on medicinal agents. IV. Conformational analysis of ephedrine isomers and related compounds","volume":"10","author":"Shafi'ee A","year":"1969","journal-title":"J Med Chem"},{"key":"e_1_2_1_133_1","unstructured":"Shire Pharmaceuticals Ireland Limited.2006. Daytrana prescribing information. Rev 04\/06."},{"key":"e_1_2_1_134_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/COPD.S2342","article-title":"Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug","volume":"3","author":"Shlomi D","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_2_1_135_1","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)11878-8","article-title":"The gastric secretion of drugs: a pH partion hypothesis","volume":"119","author":"Shore PA","year":"1957","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_136_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666080-00008"},{"key":"e_1_2_1_137_1","first-page":"19","article-title":"Treatment of children with attention\u2010deficit\/hyperactivity disorder: results of a randomized, multicenter, double\u2010blind, crossover study of extended\u2010release dexmethylphenidate and d,l\u2010methylphenidate and and placebo in a laboratory classroom setting","volume":"41","author":"Silva R","year":"2008","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_1_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(97)00175-7"},{"key":"e_1_2_1_139_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.3.387"},{"key":"e_1_2_1_140_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.1074"},{"key":"e_1_2_1_141_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.185"},{"key":"e_1_2_1_142_1","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1542\/peds.98.4.748","article-title":"Methylphenidate dosing twice daily versus three times daily","volume":"98","author":"Stein MA","year":"1996","journal-title":"Pediatrics"},{"key":"e_1_2_1_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2007.11.009"},{"key":"e_1_2_1_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70038-X"},{"key":"e_1_2_1_145_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.2.204"},{"key":"e_1_2_1_146_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370200601S10"},{"key":"e_1_2_1_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-4328(01)00433-8"},{"key":"e_1_2_1_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(61)90100-9"},{"key":"e_1_2_1_149_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.416"},{"key":"e_1_2_1_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-6238(02)00044-8"},{"key":"e_1_2_1_151_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.10018"},{"key":"e_1_2_1_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-3057(02)01073-0"},{"key":"e_1_2_1_153_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP45662"},{"key":"e_1_2_1_154_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03004146"},{"key":"e_1_2_1_155_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.8.905"},{"key":"e_1_2_1_156_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.189473"},{"key":"e_1_2_1_157_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.11.1909"},{"key":"e_1_2_1_158_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10075"},{"key":"e_1_2_1_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10038"},{"key":"e_1_2_1_160_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200111000-00002"},{"key":"e_1_2_1_161_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0101"},{"key":"e_1_2_1_162_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000138351.98604.92"},{"key":"e_1_2_1_163_1","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815a56f1"},{"key":"e_1_2_1_164_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e31816bffdf"},{"key":"e_1_2_1_165_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0b013e3280143226"},{"key":"e_1_2_1_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2007.01.108"},{"key":"e_1_2_1_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(78)90081-3"},{"key":"e_1_2_1_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.04.015"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.992","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.992","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T02:06:58Z","timestamp":1738721218000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,2]]},"references-count":167,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1002\/hup.992"],"URL":"https:\/\/doi.org\/10.1002\/hup.992","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,2]]}}}